Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A
Abstract
:1. Introduction
2. Experimental Section
2.1. Patients and Clinical Data
2.2. Blood Sampling
2.3. Serum CCL18 Measurement by Monoplex Bead Array
2.4. Single Nucleotide Polymorphism (SNP) Genotyping and mRNA Expression Analysis
2.5. Statistical Analysis
3. Results
3.1. Derivation Cohort
3.2. CCL18 Genotypes and Allele Carrier Frequencies
3.3. Serum CCL18 Levels and CCL18 Genotypes
3.4. CCL18 Genotypes and mRNA Expression
3.5. Progression of Disease and Survival in IPF Patients
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Lederer, D.J.; Martinez, F.J. Idiopathic Pulmonary Fibrosis. N. Engl. J. Med. 2018, 378, 1811–1823. [Google Scholar] [CrossRef]
- King, T.E.; Bradford, W.Z.; Castro-Bernardini, S.; Fagan, E.A.; Glaspole, I.; Glassberg, M.K.; Gorina, E.; Hopkins, P.M.; Kardatzke, D.; Lancaster, L.; et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014, 370, 2083–2092. [Google Scholar] [CrossRef] [Green Version]
- Richeldi, L.; Du Bois, R.M.; Raghu, G.; Azuma, A.; Brown, K.K.; Costabel, U.; Cottin, V.; Flaherty, K.R.; Hansell, D.M.; Inoue, Y.; et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014, 370, 2071–2082. [Google Scholar] [CrossRef] [Green Version]
- Somogyi, V.; Chaudhuri, N.; Torrisi, S.E.; Kahn, N.; Müller, V.; Kreuter, M. The therapy of idiopathic pulmonary fibrosis: What is next? Eur. Respir. Rev. 2019, 28, 190021. [Google Scholar] [CrossRef] [Green Version]
- Ley, B.; Collard, H.R.; King, T.E. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011, 183, 431–440. [Google Scholar] [CrossRef] [PubMed]
- Moeller, A.; Gilpin, S.E.; Ask, K.; Cox, G.; Cook, D.; Gauldie, J.; Margetts, P.J.; Farkas, L.; Dobranowski, J.; Boylan, C.; et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009, 179, 588–594. [Google Scholar] [CrossRef] [PubMed]
- Maher, T.M.; Stowasser, S.; Nishioka, Y.; White, E.S.; Cottin, V.; Noth, I.; Selman, M.; Rohr, K.B.; Michael, A.; Ittrich, C.; et al. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): A randomised, placebo-controlled study. Lancet Respir. Med. 2019, 7, 771–779. [Google Scholar] [CrossRef] [Green Version]
- Maher, T.M.; Oballa, E.; Simpson, J.K.; Porte, J.; Habgood, A.; Fahy, W.A.; Flynn, A.; Molyneaux, P.L.; Braybrooke, R.; Divyateja, H.; et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: An analysis from the multicentre PROFILE cohort study. Lancet Respir. Med. 2017, 5, 946–955. [Google Scholar] [CrossRef] [Green Version]
- Kinder, B.W.; Brown, K.K.; McCormack, F.X.; Ix, J.H.; Kervitsky, A.; Schwarz, M.I.; King, T.E. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009, 135, 1557–1563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kinder, B.W.; Brown, K.K.; Schwarz, M.I.; Ix, J.H.; Kervitsky, A.; King, T.E. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008, 133, 226–232. [Google Scholar] [CrossRef]
- Barlo, N.P.; van Moorsel, C.H.M.; Ruven, H.J.T.; Zanen, P.; van den Bosch, J.M.M.; Grutters, J.C. Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffus. Lung Dis. 2009, 26, 155–161. [Google Scholar]
- Greene, K.E.; King, T.E.; Kuroki, Y.; Bucher-Bartelson, B.; Hunninghake, G.W.; Newman, L.S.; Nagae, H.; Mason, R.J. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur. Respir. J. 2002, 19, 439–446. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Neighbors, M.; Cabanski, C.R.; Ramalingam, T.R.; Sheng, X.R.; Tew, G.W.; Gu, C.; Jia, G.; Peng, K.; Ray, J.M.; Ley, B.; et al. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: Post-hoc assessment of the CAPACITY and ASCEND trials. Lancet Respir. Med. 2018, 6, 615–626. [Google Scholar] [CrossRef]
- Prasse, A.; Pechkovsky, D.V.; Toews, G.B.; Jungraithmayr, W.; Kollert, F.; Goldmann, T.; Vollmer, E.; Müller-Quernheim, J.; Zissel, G. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am. J. Respir. Crit. Care Med. 2006, 173, 781–792. [Google Scholar] [CrossRef] [Green Version]
- Prasse, A.; Pechkovsky, D.V.; Toews, G.B.; Schäfer, M.; Eggeling, S.; Ludwig, C.; Germann, M.; Kollert, F.; Zissel, G.; Müller-Quernheim, J. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum. 2007, 56, 1685–1693. [Google Scholar] [CrossRef]
- Prasse, A.; Probst, C.; Bargagli, E.; Zissel, G.; Toews, G.B.; Flaherty, K.R.; Olschewski, M.; Rottoli, P.; Müller-Quernheim, J. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009, 179, 717–723. [Google Scholar] [CrossRef]
- Schupp, J.; Becker, M.; Günther, J.; Müller-Quernheim, J.; Riemekasten, G.; Prasse, A. Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. Eur. Respir. J. 2014, 43, 1530–1532. [Google Scholar] [CrossRef] [Green Version]
- Pechkovsky, D.V.; Prasse, A.; Kollert, F.; Engel, K.M.Y.; Dentler, J.; Luttmann, W.; Friedrich, K.; Müller-Quernheim, J.; Zissel, G. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin. Immunol. 2010, 137, 89–101. [Google Scholar] [CrossRef]
- Cai, M.; Bonella, F.; He, X.; Sixt, S.U.; Sarria, R.; Guzman, J.; Costabel, U. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases. Respir. Med. 2013, 107, 1444–1452. [Google Scholar] [CrossRef] [Green Version]
- Schupp, J.C.; Binder, H.; Jäger, B.; Cillis, G.; Zissel, G.; Müller-Quernheim, J.; Prasse, A. Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis. PLoS ONE 2015, 10, e0116775. [Google Scholar] [CrossRef] [Green Version]
- Kodera, M.; Hasegawa, M.; Komura, K.; Yanaba, K.; Takehara, K.; Sato, S. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: A sensitive indicator of active pulmonary fibrosis. Arthritis Rheum. 2005, 52, 2889–2896. [Google Scholar] [CrossRef] [PubMed]
- Tiev, K.P.; Hua-Huy, T.; Kettaneh, A.; Gain, M.; Duong-Quy, S.; Tolédano, C.; Cabane, J.; Dinh-Xuan, A.T. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur. Respir. J. 2011, 38, 1355–1360. [Google Scholar] [CrossRef] [PubMed]
- Adema, G.J.; Hartgers, F.; Verstraten, R.; de Vries, E.; Marland, G.; Menon, S.; Foster, J.; Xu, Y.; Nooyen, P.; McClanahan, T.; et al. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 1997, 387, 713–717. [Google Scholar] [CrossRef] [PubMed]
- Atamas, S.P.; Luzina, I.G.; Choi, J.; Tsymbalyuk, N.; Carbonetti, N.H.; Singh, I.S.; Trojanowska, M.; Jimenez, S.A.; White, B. Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 2003, 29, 743–749. [Google Scholar] [CrossRef]
- Hägg, D.A.; Olson, F.J.; Kjelldahl, J.; Jernås, M.; Thelle, D.S.; Carlsson, L.M.S.; Fagerberg, B.; Svensson, P.-A. Expression of chemokine (C-C motif) ligand 18 in human macrophages and atherosclerotic plaques. Atherosclerosis 2009, 204, e15–e20. [Google Scholar] [CrossRef]
- Modi, W.S.; Lautenberger, J.; An, P.; Scott, K.; Goedert, J.J.; Kirk, G.D.; Buchbinder, S.; Phair, J.; Donfield, S.; O’Brien, S.J.; et al. Genetic variation in the CCL18-CCL3-CCL4 chemokine gene cluster influences HIV Type 1 transmission and AIDS disease progression. Am. J. Hum. Genet. 2006, 79, 120–128. [Google Scholar] [CrossRef] [Green Version]
- Raghu, G.; Rochwerg, B.; Zhang, Y.; Garcia, C.A.C.; Azuma, A.; Behr, J.; Brozek, J.L.; Collard, H.R.; Cunningham, W.; Homma, S.; et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2015, 192, e3–e19. [Google Scholar] [CrossRef]
- Barrett, J.C.; Fry, B.; Maller, J.; Daly, M.J. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21, 263–265. [Google Scholar] [CrossRef] [Green Version]
- Stephens, M.; Smith, N.J.; Donnelly, P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 2001, 68, 978–989. [Google Scholar] [CrossRef] [Green Version]
- Pardo, A.; Smith, K.M.; Abrams, J.; Coffman, R.; Bustos, M.; McClanahan, T.K.; Grein, J.; Murphy, E.E.; Zlotnik, A.; Selman, M. CCL18/DC-CK-1/PARC up-regulation in hypersensitivity pneumonitis. J. Leukoc. Biol. 2001, 70, 610–616. [Google Scholar]
- Wells, A.U.; Flaherty, K.R.; Brown, K.K.; Inoue, Y.; Devaraj, A.; Richeldi, L.; Moua, T.; Crestani, B.; Wuyts, W.A.; Stowasser, S.; et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir. Med. 2020, 8, 453–460. [Google Scholar] [CrossRef]
- Flaherty, K.R.; Wells, A.U.; Cottin, V.; Devaraj, A.; Walsh, S.L.F.; Inoue, Y.; Richeldi, L.; Kolb, M.; Tetzlaff, K.; Stowasser, S.; et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N. Engl. J. Med. 2019, 381, 1718–1727. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Characteristics | Derivation Cohort (n = 77) | |||
---|---|---|---|---|
rs2015086 Genotype | All (n = 77) | CT (n = 18) | TT (n = 59) | p |
Male, n (%) | 58 (75) | 11 (61) | 47 (79) | 0.200 |
Age, years (IQR) | 61.4 (54–72) | 61.3 (53–75) | 62.8 (52–74) | 0.900 |
Former or active smoker, n (%) | 59 (76) | 11 (61) | 48 (81) | 0.950 |
Baseline %FVC predicted (IQR) | 75.7 (62–87) | 73.7 (52–88) | 75.7 (63–89) | 0.700 |
Baseline %DLCO predicted (IQR) | 42.5 (33–56) | 40.4 (32–64) | 47 (31–60) | 0.300 |
Polymorphism | Allele and Genotype | IPF (n = 77) | Healthy Controls (n = 349) * |
---|---|---|---|
rs712040 | C | 16 (10%) | 86 (12%) |
T | 138 (90%) | 612 (88%) | |
CC | 0 (0%) | 7 (2%) | |
CT | 16 (21%) | 72 (21%) | |
TT | 61 (79%) | 270 (77%) | |
rs2015086 * | C | 18 (12%) | 101 (15%) |
T | 136 (88%) | 593 (85%) | |
CC | 0 (0%) | 10 (3%) | |
CT | 18 (23%) | 81 (23%) | |
TT | 59 (77%) | 256 (74%) | |
rs712042 | A | 136 (88%) | 597 (86%) |
G | 18 (12%) | 101 (14%) | |
AA | 59 (77%) | 258 (74%) | |
AG | 18 (23%) | 81 (23%) | |
GG | 0 (0%) | 10 (3%) | |
rs712044 | A | 97 (63%) | 480 (69%) |
G | 57 (37%) | 218 (31%) | |
AA | 33 (43%) | 172 (49%) | |
AG | 31 (40%) | 136 (39%) | |
GG | 13 (17%) | 41 (12%) |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wiertz, I.A.; Moll, S.A.; Seeliger, B.; Barlo, N.P.; van der Vis, J.J.; Korthagen, N.M.; Rijkers, G.T.; Ruven, H.J.T.; Grutters, J.C.; Prasse, A.; et al. Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A. J. Clin. Med. 2020, 9, 1940. https://doi.org/10.3390/jcm9061940
Wiertz IA, Moll SA, Seeliger B, Barlo NP, van der Vis JJ, Korthagen NM, Rijkers GT, Ruven HJT, Grutters JC, Prasse A, et al. Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A. Journal of Clinical Medicine. 2020; 9(6):1940. https://doi.org/10.3390/jcm9061940
Chicago/Turabian StyleWiertz, Ivo A., Sofia A. Moll, Benjamin Seeliger, Nicole P. Barlo, Joanne J. van der Vis, Nicoline M. Korthagen, Ger T. Rijkers, Henk J.T. Ruven, Jan C. Grutters, Antje Prasse, and et al. 2020. "Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A" Journal of Clinical Medicine 9, no. 6: 1940. https://doi.org/10.3390/jcm9061940